Campbell McInnes
Affiliations: | Pharmaceutical Science | University of South Carolina, Columbia, SC |
Area:
Pharmacy, BiochemistryGoogle:
"Campbell McInnes"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chapagai D, Merhej G, McInnes C, et al. (2023) Structural Basis for Variations in Polo-like Kinase 1 Conformation and Intracellular Stability Induced by ATP-Competitive and Novel Noncompetitive Abbapolin Inhibitors. Acs Chemical Biology. 18: 1642-1652 |
| Chen M, Li J, Zhang L, et al. (2023) CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins. Nucleic Acids Research |
| Stafford JM, Wyatt MD, McInnes C. (2022) Inhibitors of the PLK1 Polo-Box domain: drug design strategies and therapeutic opportunities in cancer. Expert Opinion On Drug Discovery |
| Craig SN, Baxter M, Chapagai D, et al. (2021) Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. European Journal of Medicinal Chemistry. 227: 113926 |
| Chapagai D, Ramamoorthy G, Varghese J, et al. (2021) Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. Journal of Medicinal Chemistry |
| Brummer T, McInnes C. (2020) RAF kinase dimerization: implications for drug discovery and clinical outcomes. Oncogene |
| Baxter M, Chapagai D, Craig S, et al. (2020) Peptidomimetic Polo-Box targeted inhibitors that engage PLK1 in tumor cells and are selective against the PLK3 tumor suppressor. Chemmedchem |
| Beneker CM, Rovoli M, Kontopidis G, et al. (2019) Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. Journal of Medicinal Chemistry. 62: 3886-3897 |
| Chapagai DP, Baxter M, Ramamoorthy G, et al. (2019) Abstract 4712: Selective polo-like kinase 1 PBD inhibitor Cancer Research. 79: 4712-4712 |
| Pearson RJ, Blake DG, Mezna M, et al. (2018) The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. Cell Chemical Biology |